Financial Survey: Organigram Global (OGI) & The Competition

Organigram Global (NASDAQ:OGI) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Organigram Global to similar companies based on the strength of its profitability, institutional ownership, valuation, earnings, risk, analyst recommendations and dividends.

Insider & Institutional Ownership

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.1% of Organigram Global shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Organigram Global has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Organigram Global’s competitors have a beta of 2.56, indicating that their average stock price is 156% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Organigram Global and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	0	1	2	0	2.67
Organigram Global Competitors	4257	10483	18211	824	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.28%. Given Organigram Global’s competitors higher possible upside, analysts plainly believe Organigram Global has less favorable growth aspects than its competitors.

Profitability

This table compares Organigram Global and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	28.14%	-13.39%	-8.67%
Organigram Global Competitors	-278.23%	-150.06%	-21.87%

Earnings & Valuation

This table compares Organigram Global and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organigram Global	$185.07 million	-$17.70 million	2.10
Organigram Global Competitors	$1.89 billion	$138.79 million	10.83

Organigram Global’s competitors have higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Organigram Global competitors beat Organigram Global on 8 of the 13 factors compared.

Organigram Global Company Profile

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.